Increasing Recombinant Protein Expression in Insect Cells

Similar documents
BaculoDirect Baculovirus Expression System Free your hands with the BaculoDirect Baculovirus Expression System

Insect Cell Culture- General Information

the science of baculovirus expression

TransIT Transfection Reagent

Technologies for Monoclonal Antibody Production

Improving GS-CHO Cell Line Selection: Reducing Time to Clinic

Accelerating drug development to FTIH: Potential of new expression technologies

Production of proteins for medical use in TG silkworms

The Importance of Developing a High Yield of Product

Expression and Purification of Recombinant Protein in bacteria and Yeast. Presented By: Puspa pandey, Mohit sachdeva & Ming yu

ESTABLISHMENT OF CELL LINES FOR MANUFACTURING RECOMBINANT ANTIBODIES. Dr Andrew Racher

How To Develop A Cell Line

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE Q5B

NIH Mammalian Gene Collection (MGC)

Integrated Protein Services

Challenges in the cgmp Manufacturing of hescs: Lessons Learned from Monoclonal Antibodies

MEF Starter Nucleofector Kit

Integrated Protein Services

European Medicines Agency

Production of antigens and antibodies in plants: alternative technology?

SCANTIBODIES Laboratory, Inc. Contract Monoclonal Antibody Production

Growth and Maintenance of Insect Cell Lines

LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals

LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals

Overview of Upstream and Downstream Processing of Biopharmaceuticals

Luca Romagnoli, Ph.D. Business Development Manager

MEF Nucleofector Kit 1 and 2

Manufacturing process of biologics

A customizable ADCC assay service for antibodies & fusion proteins.

Fast, easy and effective transfection reagent for mammalian cells

ELISA BIO 110 Lab 1. Immunity and Disease

Customer Application Brief. Filtration Processes Applied in Therapeutic Monoclonal Antibody Production. Bioprocess, Biologicals, & Pharmaceutical

Custom Antibody Services

Protein Synthesis and Purification: Microbial Versus Mammalian Systems

Selection of Cell Lines for Manufacturing Therapeutic Antibodies by Flow Cytometric Cell Sorting. Andrew Racher Lonza Biologics

Vaccine Production Strategies: Ensuring Alignment and Sustainability

MAB Solut. MABSolys Génopole Campus 1 5 rue Henri Desbruères Evry Cedex. is involved at each stage of your project

Instructions. Torpedo sirna. Material. Important Guidelines. Specifications. Quality Control

Quick Guide to AlphaScreen SureFire Assay Optimization

Recombinant DNA and Biotechnology

Transfection reagent for visualizing lipofection with DNA. For ordering information, MSDS, publications and application notes see

About Our Products. Blood Products. Purified Infectious/Inactivated Agents. Native & Recombinant Viral Proteins. DNA Controls and Primers for PCR

3 Chapter Three: Material and methods (clone creation, upstream and downstream process)

BioBusiness Biopharmaceutical Ingredients Recombinant albumins & albumin fusion Dermot Pearson, Strategic Product Director, NZ Biopharma

Protein Expression. A Practical Approach J. HIGGIN S

INTERFERin in vitro sirna/mirna transfection reagent PROTOCOL. 1 Standard sirna transfection of adherent cells... 2

Transfection-Transfer of non-viral genetic material into eukaryotic cells. Infection/ Transduction- Transfer of viral genetic material into cells.

TOOLS sirna and mirna. User guide

Catching the Flu: A Photo Essay

Empower 3D cell culture with simplicity and versatility. VitroGel TM 3D. a ready-to-use hydrogel system for 3D cell culture and beyond

Genetic Engineering and Biotechnology

Eden Biodesign ebook Monoclonal Antibody Production: Building the Platform

Exciting Trends in Bioprocessing

Catalent Biologics & Clinical Supplies The SMART Solution

GenScript Antibody Services

Transgenic technology in the production of therapeutic proteins

Protein Expression and Analysis. Vijay Yajnik, MD, PhD GI Unit MGH

Bio-manufacturing of antigens, antibodies and bioresearch materials

Cell Cycle Phase Determination Kit

INSULIN PRODUCTS. Jack DeRuiter

Vaccine Manufacturing Facilities of the Future. Howard L. Levine, Ph.D. Vaccines Europe London, England December 1 2, 2010

Recombinant protein vaccines produced in insect cells

2.1.2 Characterization of antiviral effect of cytokine expression on HBV replication in transduced mouse hepatocytes line

Why use passive immunity?

STOP. Before using this product, please read the Limited Use License statement below:

Introduction to Bioprocessing

Use of the ambr 250 in combination with high-throughput design and analysis tools for rapid, scalable USP development

PRODUCTION AND QUALITY CONTROL OF MEDICINAL PRODUCTS DERIVED BY RECOMBINANT DNA TECHNOLOGY

Chapter 18: Applications of Immunology

EMABling Antibody Production Platform

BIOTECHNOLOGY OPERATIONS

Expression Systems for Peptide Production

1.Gene Synthesis. 2.Peptide & Phospho-P. Assembly PCR. Design & Synthesis. Advantages. Specifications. Advantages

Recombinant Protein Expression & Purification -- Challenges & Solutions

Amaxa 4D-Nucleofector Protocol for Mouse Embryonic Stem [ES] Cells For 4D-Nucleofector X Unit Transfection in suspension

BioProcessing J O U R N A L. Trends and Developments in BioProcess Technology. Volume 9 Issue 1 ISSN

Amaxa Mouse T Cell Nucleofector Kit

Especially developed for the transfection of mammalian cells with sirna or mirna

PRODUCT INFORMATION...

New Developments in Hollow-Fiber Cell Culture

From Research Services and Process Development to GMP Manufacturing

GENE CLONING AND RECOMBINANT DNA TECHNOLOGY

PlantForm Corporation

Adeno-Associated Viral Vectors

The Leading Gene Through Screen CRO

Accelerating Antibody Process Development: Exploring the Synergies Between Engineered Host Cells and Process Development

CytoSelect LDH Cytotoxicity Assay Kit

Before opening this package, please read the Limited Use License statement below:

Baculovirus Expression Vectors

Cellular Implants as mini-factories for the production of therapeutic antibodies against Altzheimer s disease. rapport research week Jonas Schiffmann

High yield antibody production in a disposable WAVE Bioreactor

Biopharmaceutical Process Evaluated for Viral Clearance

Proto col. GoClone Repor ter Construc ts: Sample Protocol for Adherent Cells. Tech support: Luciferase Assay System

Application Note USD3013. Monoclonal Antibody Production in Suspension CHO Culture Using Single-Use PadReactor Mini Bioreactor

Animal Pharming: The Industrialization of Transgenic Animals December 1999

Analyzing antibody sequence for recombinant antibody expression. Hangxing Yu, Ph.D Senior Scientist, GenScript May 20, 2015

Figure 4.1: Gel picture showing Generation of HIV-1subtype C codon optimized env expressing recombinant plasmid pvax-1:

Taqman TCID50 for AAV Vector Infectious Titer Determination

MLX BCG Buccal Cell Genomic DNA Extraction Kit. Performance Characteristics

Single Step Clarification & Capture of a Recombinant Protein from E. coli Osmotic Shock by Crossflow Chromatography

Transcription:

Increasing Recombinant Protein Expression in Insect Cells

An Insect and Mammalian Cell Culture Media Company Contract Manufacturing

Platform to Produce Recombinant Protein Cells Media Vector Culture Vessel

Cell Type Cell line choice is influenced by a number of factors What is the goal? ie virus production is typically done in Spodoptera cells Is there a licensing fee? How easy is it to grow? Does it actually express my protein of interest? Does the produced protein have the characteristics I want?

Trichoplusia vs Spodoptera 8 kd Protein 5 kd Protein 6 5 4 8 mg/l 3 PRO Sf9 6 4 PRO Sf9 Day 3 Day 4 Day 3 Day 4 Expression of secreted proteins. Both cell lines were infected at an MOI of.

Do the Glycosylation Patterns Seen Suit My Protein? Eukaryotic processing but not mammalian type This may or may not influence application Absence of terminal sialic acids is often unacceptable for therapeutics Watanabe, S. et al. J. Biol. Chem. ;77:59-593

Altering Glycosylation Patterns Transgenic insect cell lines were made by transforming with mammalian genes SfSWT- cells were transformed with 5 mammalian glycosyltransferases Expression of rtsh is enhanced compared to parental Sf9 cells ng/ml 5 5 5 Sf9 SfSWT-

Vector Choice Shuttle vectors allow for a variety of modifications Targeting signals, purification tags, promoter choice, enhancers Vectors for stable cell line Basis of lytic vectors is AcMNPV with modifications of the backbone Deletions, manipulations for ease of use

Promoter Usage Expression of a secreted protein in PRO cells Secretion enhanced with honeybee mellitin signal Cells were infected at an MOI of and harvested day 4 mg/l 9 8 7 6 5 4 3 p ph *In progress* p6.9

Media Manipulations Serum supplemented media Serum-free and protein-free formulations Additives Future Directions- Chemically defined Optimized for stable cells versus shorter term lytic production runs

Supplementation over course of production Secreted Protein mg/l 9 8 7 6 5 4 3 Day 3 Day 4 PRO PRO PBA Cells were infected at an MOI of. Production Boost Additive was delivered as 5% of the total culture volume 8 hours post infection.

Timing of Viral Infection Experiment: Take Sf9 cells from seed stock and inoculate flask at 6 /ml Let grow overnight so they are in log phase 4 35 3 5 mg/l 5 5 Mid Conc High Conc Infect at MOI of 7 3 4 5 9 6 8 7 5 6 5 4 3 U/ml 4 3 Mid Conc High Conc 3 4 5 3 4 5

Low MOI Experiment Hypothesis: Infecting with a low MOI may increase overall recombinant protein yield Sf9 cells were infected rbv expressing human transferrin as a model of a secreted protein Samples taken over timecourse to determine cell count, viability, spread of bv infection, and protein production

gp64 Staining Over Range of MOI % Positive 9 8 7 6 5 4 3 3 4 5 Day of Infection.E+.E-.E-.E-3.E-4.E-5 gp64 expression demonstrates spread of virus

Total Number of Infected Cells Increases with Lower MOI 6 # of Infected Cells per ml 5 4 3 3 4 5 Days of Infection.E+.E-.E-.E-3.E-4.E-5 Uninfected cells do not undergo growth arrest leading to more targets for viral spread

Viral Burst Size Cells grown in suspension in ESF 9 Viral infection determined by gp64 staining Titers determined by flow cytometric method Assumes generation time of 4 hours Estimation based on low MOI expt with Sf9 cells: 3 viruses per generation

What is the predicted amount of MOI (-) (-) (-3) (-4) (-5) virus produced and resulting MOI? Virus Produced 3. x 8. x 8.64 x 7 # of targets 3.5 x 6 4.84 x 6 4.48 x 6 Effective MOI x 6 /ml 6 5 4 3 # of Infected Cells (-) (-) (-3) (-4) (-5)

What is the predicted amount of MOI (-) (-) (-3) (-4) (-5) virus produced and resulting MOI? Virus Produced 3. x 8. x 8.64 x 7 # of targets 3.5 x 6 4.84 x 6 4.48 x 6 Effective MOI 99 x 6 /ml 6 5 4 3 # of Infected Cells (-) (-) (-3) (-4) (-5)

What is the predicted amount of MOI (-) (-) (-3) (-4) (-5) virus produced and resulting MOI? Virus Produced 3. x 8. x 8.64 x 7 # of targets 3.5 x 6 4.84 x 6 4.48 x 6 Effective MOI 99 x 6 /ml 6 5 4 3 # of Infected Cells (-) (-) (-3) (-4) (-5)

What is the predicted amount of MOI (-) (-) (-3) (-4) (-5) virus produced and resulting MOI? Virus Produced 3. x 8. x 8.64 x 7 # of targets 3.5 x 6 4.84 x 6 4.48 x 6 Effective MOI 99 3.7 x 6 /ml 6 5 4 3 # of Infected Cells (-) (-) (-3) (-4) (-5)

Does the estimated MOI meet our predictions? MOI (-) (-) (-3) (-4) (-5) Virus Produced 3. x 8. x 8.64 x 7 # of targets 3.5 x 6 4.84 x 6 4.48 x 6 Effective MOI 99 3.7 Percentage of Infected Cells 8 7 6 5 4 3 (-) (-) (-3) (-4) (-5)

Taking it a step further- Predicting spread in the -3 culture MOI (-) (-) (-3) (-4) Virus Produced 3. x 8. x 8.64 x 7 Assume.64 x 6 # of targets 3.5 x 6 4.84 x 6 4.48 x 6 Effective MOI 99 3.7 x 6 /ml 6 5 4 3 # of Infected Cells (-) (-) (-3) (-4) (-5) (-5)

Taking it a step further- Predicting spread in the -3 culture MOI (-) (-) (-3) (-4) Virus Produced 3. x 8. x 8.64 x 7 Assume.64 x 6 # of targets 3.5 x 6 4.84 x 6 4.48 x 6 5. x 6 Effective MOI 99 3.7 x 6 /ml 6 5 4 3 # of Infected Cells (-) (-) (-3) (-4) (-5) (-5)

Taking it a step further- Predicting spread in the -3 culture MOI (-) (-) (-3) (-4) Virus Produced 3. x 8. x 8.64 x 7 Assume.64 x 6 # of targets 3.5 x 6 4.84 x 6 4.48 x 6 5. x 6 Effective MOI.3 99 3.7 x 6 /ml 6 5 4 3 # of Infected Cells (-) (-) (-3) (-4) (-5) (-5)

Taking it a step further- Predicting spread in the -3 culture MOI of.3 times 5. x 6 targets =.64 x 6 infected cells/ml # of infected cells determined by cell counts and staining:.83 x 6 x 6 /ml 6 5 4 3 # of Infected Cells (-) (-) (-3) (-4) (-5)

Production of human Transferrin 35 3 mg/l 5 5 5 MOI = MOI = (-) MOI = (-) MOI = (-3) MOI = (-4) 3 4 5 6 7

Low MOI with PBA Hypothesis: The high cell density that occurs when using a low MOI may benefit from a nutritive boost to maintain cell health Experiment: Infect Sf9 cells at an MOI of -. Add PBA after the bulk of the cells are infected with baculovirus.

Production of human Transferrin 45 4 mg/l 35 3 5 5 5 % PBA 5% PBA % PBA No PBA Control Day 3 Day 4 Day 5 Day 6 PBA was added 36 hours after the addition of virus Cell count at the time of PBA addition was between - x 6 cells/ml

Low MOI Expression in PRO cells PRO cells are derived from T.ni embryos Cells were infected at an MOI of and. 7 hour harvest shows higher MOI to be superior 5 5 5 MOI=. MOI= 3

Low MOI Expression in PRO cells PRO cells are derived from T.ni embryos Cells were infected at an MOI of and. 7 hour harvest shows higher MOI to be superior Waiting an extra day can have dramatic benefits 9 8 7 6 5 4 3 3 4 MOI=. MOI=

Platform-Build Your Own? Cells: Sf9, Sf, Tni, Ea4, S, Bm4, Dpn, etc etc Culture Vessels: Fermentor WAVE Fernbach Plates Scale: mls to Ls Vectors: Lytic-Bacmid Bacpak, etc Stable Transient Promoter choices Media: Serum-free Protein-free Animal-free Additives

High Throughput Screening Rapid screening to speed time to target Two cell lines to maximize possibility of detecting product Plaque purification of virus can wait until candidates are selected Small scale expressions (<L) benefit from quality media but fine tuning not necessary

Production of Protein of Interest Pick cell line that creates product with most desirable characteristics Pick vectors that help streamline purification downstream Purification tags, enhancement of solubility Pick stable vector, plaque purify, maintain low passage virus Maximize cell density during production Fine tune media formulation specific to protein

Acknowledgments Brooks Hayes Aaron McKinney Ron Makishima Allen Rodrigo- University of Auckland Don Jarvis- University of Wyoming Loy Volkman- UC Berkeley